Gurpreet Baweja, MD
Interventional Cardiology · Ft Worth, TXNPI 1861614638
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $8,877 of the $14,630 with a category attached, or 60.7%. Medtronic accounts for 61.4% of it on its own, with 23 other manufacturers making up the rest. 2025 is the largest year on record at $10,585, 7.2 times the $1,472 reported in 2019.
Across 200 payments — averaging $73.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$9K
- Boston Scientific$2K
- Cardiovascular Systems Inc.$1K
- Abbott$817
- Abiomed$362
- Biotronik Inc.$251
- plus $2K from 18 others
Across 31 payments — averaging $8916.22 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$248K
- Kowa Research Institute, Inc.$25K
- Abbott$4K
What the payments were for
- Travel & lodging$8,87761%
- Food & beverage$5,65339%
- Education$1001%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 28 | $8,979 |
| Boston Scientific | 21 | $1,625 |
| Cardiovascular Systems Inc. | 38 | $1,074 |
| Abbott | 27 | $817 |
| Abiomed | 6 | $362 |
| Biotronik Inc. | 2 | $251 |
| Amgen | 11 | $189 |
| Astellas Pharma US Inc | 7 | $181 |
| E.r. Squibb & Sons, L.L.C. | 8 | $165 |
| Pfizer | 9 | $163 |
| Johnson & Johnson | 11 | $149 |
| Penumbra, Inc. | 1 | $144 |
| Novartis | 7 | $133 |
| Shockwave Medical, Inc | 3 | $86 |
| Sanofi-aventis U.S. LLC | 4 | $69 |
| AstraZeneca | 5 | $61 |
| Boehringer Ingelheim | 3 | $45 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $33 |
| Teleflex LLC | 1 | $23 |
| Getinge USA Sales, LLC | 1 | $20 |
| Convatec Inc. | 1 | $18 |
| Heartflow, Inc. | 1 | $16 |
| Angiodynamics, Inc. | 1 | $15 |
| Chiesi USA, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL - THERAPIES$760
- AVVIGO Guidance System$429
- ONYX FRONTIER$306
- Coronary Orbital Atherectomy System$258
- Orsiro Mission$251
- Impella$180
- OPTIS$178
- Indigo$144
- Diamondback Coronary$122
- Watchman$119
- AMPLATZER AMULET$112
How this compares
$14,630 in reported general payments places this provider in the 65th percentile of 686 interventional cardiology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 406 | $467,367 |
| XareltoRivaroxaban | 100 | $104,085 |
| JardianceEmpagliflozin | 63 | $59,070 |
| Praluent PenAlirocumab | 19 | $13,281 |
| Repatha SureclickEvolocumab | 12 | $12,313 |
| EntrestoSacubitril/Valsartan | 17 | $10,679 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 18 | $6,728 |
| Metoprolol Succinate | 391 | $5,255 |
| ClopidogrelClopidogrel Bisulfate | 251 | $3,579 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 120 | $3,533 |
| Ranolazine ErRanolazine | 33 | $3,161 |
| Flecainide Acetate | 81 | $2,749 |
| Atorvastatin Calcium | 204 | $2,419 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 211 | $2,408 |
| SotalolSotalol Hcl | 83 | $2,066 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $163 | $467,367406 claims |
| Johnson & JohnsonXarelto | $149 | $104,085100 claims |
| Boehringer IngelheimJardiance | $45 | $59,07063 claims |
| NovartisEntresto | $133 | $10,67917 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 686 interventional cardiology providers in Texas.
Other interventional cardiology in Ft Worth
- Juan GranadaHouston$4.1M
- Vamsi KrishnaKyle$2M
- Jeffrey CarrTyler$1.9M
- John IsaacHouston$1.8M
- Robert ChiltonSan Antonio$1.3M
- Sameh SayfoPlano$1M
- Srinivasa PotluriPlano$781K
- Karim Al-AziziPlano$734K
- Robert StolerDallas$587K
- Peter MonteleoneKyle$461K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.